Head and neck squamous
cell carcinoma (HNSCC) is the
sixth most
prevalent cancer in the world and the most prevalent cancer of developing
countries. Increased disease burden and a smaller number of approved
targeted therapies are a growing concern worldwide. Isoindolinone
motifs have been a central part of many pharmacological compounds,
and their derivatives possess substantial anticancer potential. However,
their anticancer potential against HNSCC has not been well investigated.
In the current study, a series of 3-methyleneisoindolinones have been
designed and synthesized and their late-stage intramolecular Heck
cyclization was achieved to evaluate their anticancer potential against
HNSCC cells. Additionally, in silico ADME profiling
of synthesized compounds revealed their drug-likeness properties as
potential drug candidates. Among the synthesized compounds, 3-bromo-5-methylpyridin-2-yl-3-methyleneisoindolin-1-one,
i.e., 3n, with a pyridyl unit exhibited the most significant
cytotoxicity against HNSCC cells. The cytotoxic potential of synthesized
compounds varied depending on the nature of substituents present and
has been well established with structure–activity relationship
studies. Further, flow cytometric analysis showed that 3f, 3h, and 3n triggered intracellular oxidative
stress, disrupted mitochondrial membrane potential, and interrupted
the cell cycle of HNSCC cells in the S-phase and sub-G1 phase. Further, 3f, 3h, and 3n also exhibited pro-apoptotic
potential and induced cellular apoptosis in the HNSCC cells. Overall,
the findings of this study attributed 3-methyleneisoindolinone chemistry
and efficacy evaluation and corroborated their anticancer potential
against HNSCC. It will pave the way to further design and optimize
novel 3-methyleneisoindolinone as effective antitumor agents, which
may provide effective treatment modalities against HNSCC.